Agent Selection for Rate and Rhythm Control in Atrial Fibrillation Based on Comorbidities

Introduction to Atrial Fibrillation Management

The American College of Cardiology recommends avoiding all AV nodal blocking agents in patients with Wolff-Parkinson-White (WPW) syndrome and atrial fibrillation (AF) as they can precipitate ventricular fibrillation by accelerating conduction through the accessory pathway, with a strength of evidence level of high 1, 2, 3
In patients with WPW and AF, immediate direct-current cardioversion is the treatment of choice for hemodynamically unstable patients, with a success rate of over 90% and a complication rate of less than 1% 1, 2, 4

For hemodynamically stable patients with pre-excited AF, IV procainamide or IV ibutilide are recommended as first-line treatments to restore sinus rhythm or slow ventricular rate, with a response rate of 70-80% 1, 2, 4
The American Heart Association recommends catheter ablation of the accessory pathway as the definitive treatment for symptomatic WPW patients, with a success rate exceeding 95% and complication rates less than 1-2% in experienced centers 1, 2, 4

The American College of Cardiology recommends IV digoxin or IV amiodarone as first-line agents for acute rate control in heart failure with reduced ejection fraction (HFrEF), with a strength of evidence level of moderate 1
For chronic rate control in HFrEF, digoxin is effective for controlling resting heart rate, with a response rate of 80-90% 1
In heart failure with preserved ejection fraction (HFpEF), beta-blockers or nondihydropyridine calcium channel antagonists are preferred for persistent or permanent AF, with a strength of evidence level of high 1

The American College of Cardiology recommends beta-blockers as the preferred agents for rate control in ACS with AF when there is no heart failure, hemodynamic instability, or bronchospasm, with a strength of evidence level of high 1
Amiodarone or digoxin may be considered in patients with severe left ventricular dysfunction, heart failure, or hemodynamic instability, with a response rate of 70-80% 1, 4

The American Thyroid Association recommends beta-blockers as the first-line agents for controlling ventricular rate in AF complicating thyrotoxicosis, with a strength of evidence level of high 1, 4
Nondihydropyridine calcium channel antagonists are recommended as alternative agents when beta-blockers cannot be used, with a response rate of 80-90% 1, 4

The American College of Chest Physicians recommends nondihydropyridine calcium channel antagonists as the preferred agents for rate control in COPD patients with AF, with a strength of evidence level of moderate 1, 2
Non-selective beta-blockers, sotalol, propafenone, and adenosine are contraindicated in patients with bronchospasm, with a strength of evidence level of high 2

The American College of Cardiology recommends warfarin as mandatory for valvular AF, particularly mitral stenosis or mechanical valves, regardless of CHA2DS2-VASc score, with a strength of evidence level of high 4

Never use AV nodal blockers in WPW with pre-excited AF, as this can cause sudden death, with a strength of evidence level of high 1, 2, 3, 5
Avoid IV calcium channel blockers and beta-blockers in decompensated heart failure, and use digoxin or amiodarone instead, with a strength of evidence level of moderate 1
Do not use dronedarone in decompensated heart failure, as it is contraindicated, with a strength of evidence level of high 1
Avoid non-selective beta-blockers in COPD/asthma, and use calcium channel blockers instead, with a strength of evidence level of high 1, 2
Always have a defibrillator immediately available when treating WPW with AF pharmacologically, even with appropriate agents like procainamide, with a strength of evidence level of high 1, 2, 3, 5
Do not perform AV node ablation without first attempting pharmacological rate control, with a strength of evidence level of moderate 1